SHPHARMA：2025FIRSTQUARTERLYREPORT.pdf

1、-1-Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in rel

2、iance upon the whole or any part of the contents of this announcement.上海醫藥集團股份有限公司Shanghai Pharmaceuticals Holding Co.,Ltd.*(A joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock Code:02607)2025 FIRST QUARTERLY REPORTThis announcement is made pursuant to P

3、art XIVA of the Securities and Futures Ordinance(Cap.571 of the Laws of Hong Kong)and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.The following is the first quarterly report for 2025 of Shanghai Pharmaceuticals Holding Co.,Ltd.The financial

4、report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.By order of the BoardShanghai Pharmaceuticals Holding Co.,Ltd.*YANG QiuhuaChairmanShanghai,the PRC,29 April 2025As of the date of this announcement,the executive Directors of

5、the Company are Mr.YANG Qiuhua,Mr.SHEN Bo,Mr.LI Yongzhong and Mr.DONG Ming;the non-executive Director is Mr.ZHANG Wenxue;and the independent non-executive Directors are Mr.GU Zhaoyang,Mr.FOK Manson,Mr.WANG Zhong and Ms.MAN Kwan.*For identification purpose only-2-The board of directors of the Company

6、 and all directors warrant that there are no false representations,or misleading statements or material omissions contained in this announcement,and assume legal liabilities for the truthfulness,accuracy and completeness thereof.IMPORTANT NOTICEThe board of directors and the board of supervisors of